Venture capital fund · 1 deal
Every published round CaraMed Capital took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Psylo | Seed | 27 Oct 2022 | $5m | Participant | Startup Daily (4 Jun 2024), SmartCompany, Startup Daily (27 Oct 2022) |
Companies CaraMed Capital has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Psylo | 27 Oct 2022, Seed | 1 | 0 |
Fund closes reported for CaraMed Capital, as distinct from the investments it has made.
Companies CaraMed Capital has backed that another company then bought. An exit for the holding, not a deal CaraMed Capital did.
Stories naming CaraMed Capital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney psychedelic biotech Psylo has banked a $5 million seed round led by CSIRO's Main Sequence Ventures, its second raise since emerging from Startmate, to advance a fast-acting psilocybin therapy toward clinical trials.